Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
1984-15-2
Molecular formula
CH6O6P2
Molecular weight
176 g/mol
Drug class
Bisphosphonate liganddiagnostic radiopharmaceutical precursor for technetium-99m skeletal imaging
Mechanism of action
Medronic acid (methylene diphosphonate, MDP) chelates technetium-99m after reconstitution of a radiopharmaceutical kit. The labelled complex has affinity for hydroxyapatite in bone and accumulates in proportion to regional blood flow and osteoblastic activity, allowing skeletal scintigraphy.
Indications / reported uses
Used as the active ligand in technetium Tc-99m medronate (Tc-99m MDP) kits for skeletal scintigraphy and imaging of areas of increased osteogenic activity. The diagnostic imaging agent is the technetium-labelled product, not unlabelled medronic acid alone.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Medronic Acid PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Medronic Acid Permitted Daily Exposure (PDE) report (the Medronic Acid PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Medronic Acid Occupational Exposure Limit (OEL) report (the Medronic Acid OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.